

STANTEC INC  
Form 8-K  
April 03, 2006

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

**FORM 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**March 31, 2006  
Date of Report (date of earliest  
event reported):**

**Stellar Pharmaceuticals Inc.**

**(Exact Name of Registrant as  
Specified in Its Charter)**

**Ontario  
(State or other jurisdiction of  
incorporation)**

**000-31198  
(Commission File Number)**

**N/A  
(IRS Employer Identification No.)**

**544 Egerton Street, London, Ontario,  
Canada  
(Address of Principal Executive  
Offices)**

**N5W 3Z8  
(Zip Code)**

**(519) - 434-1540  
(Registrant's Telephone Number, Including Area Code)**

**N/A  
(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
-

Edgar Filing: STANTEC INC - Form 8-K

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17  
CFR 240.13e-4(c))

---

TABLE OF CONTENTS

Item 2.02 Results of Operations and Financial Condition

Item 9.01 Financial Statements of Exhibits and Exhibits

SIGNATURES

Press Release

**Item 2.02 Results of Operations and Financial Condition**

On March 31, 2006, Stellar Pharmaceuticals Inc. (the "Company") issued a press release with its financial results for the year ended December 31, 2005. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

99.1 Press Release, dated March 31, 2006, issued by the Company.

The information contained in this Current Report under Item 2.02, including the exhibit referenced in Item 9.01, is being "furnished" pursuant to "Item 2.02 Results of Operations and Financial Condition" of Form 8-K and, as such, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STELLAR PHARMACEUTICALS INC.

Date: March 31, 2006

By: /s/ Janice Clarke  
Janice Clarke  
Chief Financial Officer